Aptar Pharma, a global leader in drug delivery and active material science solutions and services, announced that it has entered into an exclusive collaboration agreement with Cambridge Healthcare Innovations (CHI) to lead the commercialization and promotion of its Quattrii Dry Powder Inhaler (DPI) platform.
Exactech, a global medical technology leader, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Truliant® Porous Tibial Tray, a 3D tibial knee implant.
Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE 6523), announces its SlideMate™ Laser slide printer has received an Innovative Technology Designation for improving laboratory efficiency and sample traceability from Vizient, Inc., the largest provider-driven healthcare performance improvement company in the country.
Imbed Biosciences announces U.S. Food and Drug Administration 510(k) clearance to market Microlyte® Ag/Lidocaine, the first antimicrobial wound dressing to integrate lidocaine for the management of painful skin wounds. Microlyte® Ag/Lidocaine utilizes Imbed’s patented synthetic matrix to deliver ionic and metallic silver alongside lidocaine, providing both antimicrobial protection and local anesthetic effects.
To help improve access to fast, reliable testing for veterans, Walgreens is now offering no-cost testing through a partnership with the Centers for Disease Control and Prevention (CDC).* Eligible veterans will be able to receive an easy combination test for COVID-19 and influenza at Walgreens locations across the country throughout this year’s respiratory season, with results in 30 minutes or less.** No-cost COVID-19 and flu testing will also continue to be available at Walgreens for uninsured patients via the CDC program.
DermaSensor, a world leader in skin cancer diagnostic technology, announced the company’s inclusion in TIME’s Best Inventions of 2024 list under the Medical Care category. TIME’s prestigious award recognizes 200 innovations that TIME editors deem as the most impactful new products and ideas globally.
Shorla Oncology a U.S.-Ireland specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of JYLAMVO™ (methotrexate) to include the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (pJIA). With this approval, JYLAMVO is currently the only oral liquid methotrexate on the market approved for both adult and pediatric indications.
Advanced NanoTherapies (ANT), a clinical-stage medical device company committed to solving the most significant challenges in vascular disease through innovative applications of nanotechnology, announced positive results from its first-in-human (FIH) trial evaluating the next-generation SirPlux™ Duo Drug-Coated Balloon (DCB).
Bora Pharmaceuticals Co., Ltd. announced that its Board of Directors has approved the acquisition of US-based Pyros Pharmaceuticals, Inc. ("Pyros"), a specialty pharmaceutical company developing treatments for rare diseases.
Anixa Biosciences, Inc. "Anixa" or the a biotechnology company focused on the treatment and prevention of cancer, announced that it has administered the second dose of its CAR-T therapy to an individual patient.This follows a positive response after the initial treatment in the ongoing Phase 1 clinical trial of its chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. The study is being conducted in collaboration with Moffitt Cancer Center.